SystImmune and Bristol Myers Squibb announced positive topline results from a pre-specified interim analysis of the Phase III BL-B01D1-307 trial evaluating izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific antibody-drug conjugate, in patients with previously treated unresectable locally advanced or metastatic triple-negative breast cancer whose disease progressed after prior taxane therapy. The study met its dual primary endpoints, showing statistically significant improvement in progression-free survival and overall survival versus physician’s choice chemotherapy. The companies said the data will be presented at an upcoming medical meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20260225116016) on February 26, 2026, and is solely responsible for the information contained therein.